CD34 and sickle cell disease: Moreover, Vertex Pharmaceuticals Incorporated have proposed a phase 1/2 study to evaluate the safety and efficacy of autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (hHSPCs) using CTX001 in subjects with severe sickle cell disease (NCT03745287).